date:Oct 26, 2018
iry products and other health concepts are expected to maintain their positive growth rates. In general, Novozymes expects continued growth across industries, although the starch business in the Asia-Pacific and market constraints in the Middle East are expected to act as dampeners.
We delivered solid earnings and organic revenue growth of 5 percent in the third quarter and 4 percent after the first nine months. This is overall satisfactory, and we increase the outlook for net profit growth, Pe